Cellectis (CLLS) EBIT Growth (1y) (2016 - 2026)
Cellectis (CLLS) EBIT Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 2,150.96% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -77.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.49% |
| Dec 31, 2025 | -62.47% |
| Sep 30, 2025 | 174.67% |
| Jun 30, 2025 | 44.30% |
| Mar 31, 2025 | 32.14% |
| Dec 31, 2024 | 63.89% |
| Sep 30, 2024 | 47.90% |
| Jun 30, 2024 | 27.14% |
| Mar 31, 2024 | 10.83% |
| Dec 31, 2023 | -422.60% |
| Sep 30, 2023 | 24.43% |
| Jun 30, 2023 | 13.52% |
| Mar 31, 2023 | 19.83% |
| Dec 31, 2022 | 76.95% |
| Sep 30, 2022 | 35.44% |
| Jun 30, 2022 | 27.13% |
| Mar 31, 2022 | -46.82% |
| Dec 31, 2021 | 37.29% |
| Sep 30, 2021 | -44.34% |
| Jun 30, 2021 | -13.47% |